Trial Profile
A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLINDED TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MenABCWY IN HEALTHY PARTICIPANTS ≥10 TO <26 YEARS OF AGE
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Oct 2023
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine group B (Primary) ; Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; PF-06886992 (Primary)
- Indications Meningococcal infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Pfizer
Most Recent Events
- 20 Oct 2023 According to a Pfizer media release, the CDC Advisory Committee on Immunization Practices (ACIP) will meet on October 25, 2023, to discuss recommendations for the appropriate use of PENBRAYA in adolescents and young adults.
- 20 Oct 2023 According to a Pfizer media release, the U.S. Food and Drug Administration (FDA) has approved PENBRAYA™ (meningococcal groups A, B, C, W and Y vaccine) in adolescents and young adults 10 through 25 years of age, based on the positive results from the Phase 2 and Phase 3 trials, including this trial.
- 21 Feb 2023 According to a Pfizer media release, data from the study will be presented at the ACIP meeting 2023.